Stocks › DVA
DaVita Inc (DVA) stock analysis
WEAK BUY 18% confidence · analysed Sep 3, 2026
This analysis is from Sep 3, 2026 and may be out of date.
On Sep 3, 2026, our model rated DaVita Inc (DVA) WEAK BUY with 18% confidence at a price of $178.85. That means the signals lean positive, but they are mixed, so conviction is low.
Technical picture
The 14-day RSI is 49, close to the neutral 50 line, so momentum is balanced.
MACD is above its signal line, a sign that short-term momentum is turning up.
The price has slipped below its 50-day moving average but is still above the 200-day: a pullback inside a longer-term uptrend.
Volume is only 0.0x its 20-day average; light trading makes the latest move less convincing.
Fundamentals
The PEG ratio is 0.43, which looks cheap relative to its expected growth.
The company reports a profit margin of 6.0% and revenue growth of +5.2%.
In its latest quarter it earned $4.02 per share, which beat the $3.88 analysts expected, with revenue +5.2% year over year.
Wall Street's average rating is 2.3 on a 1 (strong buy) to 5 (sell) scale, roughly a "buy", with an average price target of $218.43.
The next earnings report is expected around Oct 28, 2026; prices often move sharply around earnings.
Trade plan from the model
The model's long / bullish plan uses an entry near $180.88, a target of $186.35 (+3.0%) and a stop-loss at $172.82 (-4.5%).
That is a reward-to-risk ratio of about 0.7 to 1: the potential loss is bigger than the gain, a weak setup.
The plan has a time limit: reassess by Sep 13, 2026 whatever the price does.
The model's one-paragraph read
Leans BUY — composite score +0.18 (WEAK BUY). Technicals: RSI 49.32, MACD bullish, price below SMA50. Fundamentals: PEG 0.43, margin 6.0%, revenue growth 5.2%. Financial results: YoY revenue +5.2%, last EPS surprise +3.6%, next earnings 2026-10-28. FinGPT news read: positive. Memory: 1 prior look(s). Suggested levels: entry $180.88, target $186.35, stop-loss $172.82, exit by 2026-09-13 (10-calendar-day max hold (time-stop; reassess by this date regardless of P&L)).
Past ratings for DVA
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Sep 3, 2026 | WEAK BUY | 18% | $178.85 | — | |
| Sep 2, 2026 | WEAK BUY | 20% | $178.77 | +0.0% | ✔ right direction |
"Move since" compares each call's price with the latest analysed price.
Other Healthcare stocks we cover
EVH · FTRE · HALO · HUM · IART · ICLR · IRWD · JNJ · KMDA · LH · LLY · MDT
Frequently asked questions
Is DVA a buy right now?
As of Sep 3, 2026, our automated model rates DaVita Inc (DVA) WEAK BUY with 18% confidence: the signals lean positive, but they are mixed, so conviction is low. This is a model output for education, not personal investment advice.
What is the price target for DVA?
The model's most recent plan targets $186.35 with a stop-loss at $172.82, from an entry near $180.88.
When does DaVita Inc report earnings next?
The next earnings report is expected around Oct 28, 2026.
What does a WEAK BUY rating mean?
A WEAK BUY rating means the signals lean positive, but they are mixed, so conviction is low.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.